8-K - Jasper Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Jasper Therapeutics reported Q4 and full year 2025 financial results with net loss of $9.1 million and $75.8 million respectively, cash of $28.7 million, and positive briquilimab data in urticaria and asthma.

Key Takeaways

1Cash and cash equivalents totaled $28.7 million as of December 31, 2025, down from $71.6 million year-end 2024.

2Q4 2025 net loss $9.1 million or ($0.32) per share, improved from ($24.3 million) or ($1.62) per share in Q4 2024.

3Full year 2025 net loss $75.8 million or ($3.95) per share versus ($71.3 million) or ($4.89) per share in 2024.

467% complete response in BEACON Cohort 9.1 at 12 weeks; 75% in open-label extension for CSU.

5On track for Phase 2b/3 CSU study enrollment in H2 2026 pending capital.

6Positive ETESIAN asthma data supports further development based on partnerships and capital.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 2.02 and Item 9.01 of Current Report on Form 8-K and shall not be d

Financial Results

9.01

. Financial Statements and Exhibits.** (d) Exhibits. | Exhibit No. | | Description | |---|---|---| | 99.1 | | Press Release, dated March 30, 2026. | | 104 | | C

Exhibits Only

Source Document

Results of Operations

Fourth Quarter Fiscal 2025

Metric	Value	Basis	Prior Period
Research and development expense	$11.4K	GAAP	$19.8K
General and administrative expense	$4.5K	GAAP	$5.5K
Net loss	$-9.1K	GAAP	$-24.3K
Net loss per share	$-0.32	GAAP	$-1.62

Exhibits (2)

8-K

CURRENT REPORT

99.1

PRESS RELEASE, DATED MARCH 30, 2026